Some aspects of interstitial lung disease associated with leflunomide therapy in patients with rheumatoid arthritis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article analyzes publications related to interstitial lung disease (ILD) caused by taking leflunomide (LEF) during the treatment of rheumatoid arthritis. Being an effective disease modifying antirheumatic drug, LEF can provoke the development of severe forms of ILD in rheumatoid arthritis with a fatal outcome. At the same time, it is possible that the process is more acute than that of methotrexate-induced IDL. Prospective randomized controlled trials are required to further evaluation of the effect of LEF on the development and course of ILD.

Full Text

Restricted Access

About the authors

D. V Bestaev

North Ossetian State Medical Academy (NOSMA)

Email: avidbestaev@rambler.ru
Dr. Sci. (Med.), Head of the Department of Internal Diseases № 3 40, Pushkinskaya str., Republic of North Ossetia-Alania, Vladikavkaz 362019, Russian Federation

Z. S Brtsieva

North Ossetian State Medical Academy (NOSMA)

Vladikavkaz, Russia

S. A Ktsoeva

North Ossetian State Medical Academy (NOSMA)

Vladikavkaz, Russia

L. M Khutieva

North Ossetian State Medical Academy (NOSMA)

Vladikavkaz, Russia

N. N Burduli

North Ossetian State Medical Academy (NOSMA)

Vladikavkaz, Russia

O. T Kotsoeva

North Ossetian State Medical Academy (NOSMA)

Vladikavkaz, Russia

T. D Bestaeva

Family Medicine Clinic

Vladikavkaz, Russia

References

  1. Насонов Е.Л. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов. Терапевтический архив. 2007;5:5-8.
  2. Бестаев Д.В., Новиков А.А., Насонов Е.Л. Cостояние Тh2-клеточного иммунитета у больных ревматоидным артритом с и без интерстициального поражения легких. Современные проблемы науки и образования. 2015;3.
  3. Hamblin M.J., Horton R.M. Rheumatoid Arthritis-Associated interstitial Lung Disease: Diagnostic Dilemma. Pulm Med. 2011;2011:1-12. doi: 10.1155/2011/872120.
  4. Бестаев Д.В., Божьева Л.А. Оценка состояния некоторых показателей функции внешнего дыхания больных ревматоидным артритом с и без интерстициального поражения легких в зависимости от динамики данных компьютерной томографии высокого разрешения легких. Лечащий врач. 2015;3:63.
  5. Бестаев Д.В., Божьева Л.А. Клиниколабораторные и инструментальные особенности больных ревматоидным артритом с компьютерно-томографическим симптомом интерстициального поражения легких «матовое стекло». Вестник новых медицинских технологий (электронное издание). 2015;1:2-19
  6. Chervinski H.M., Coln R.G., Cheung R, al. The immunosuppressant Leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther. 1995;275:1043-49.
  7. Siemasko K.F., Chong A.S.F., Williams J.W., et al. Ragulation of B cell function by the immunosuppressive agent leflunomide. Transplantation. 1996;61:635-42.
  8. Zelinski T, Muller H.J., Scheyerbach R., et al. Differential effects of leflunomide on leucocytes: inhibition of rat in vivo adhesion and human in vitro oxidative burst without affecting surface marker modulation. Agents Actions. 1994;41(Spec.):276-78.
  9. Lang R, Wagner H., Heeg K. Differential effects of the immunosuppressive agents cyclosporine and leflunomide in vivo: Leflunomide blocks clonal T cell expansion yet allows production of lymphokines and manifestation of T-cell-mediated shock. Transplantation. 1995;59:382-89. doi: 10.1097/00007890-199502000-00013.
  10. Prakash A., Jarvis B. Leflunomide: a review of its Use in Active rheumatoid Arthritis. Drugs. 1999;58:1137-64. doi: 10.2165/00003495-199958060-00010.
  11. Hamilton L., Voinovic I., Bakhle Y, et al. The antiinflammatory drug leflunomide inhibits in vitro and in vivo the activity of COX-2 more potently than the induction of COX-1 or iNOS. Br J Rheumatol. 1997;120-49.
  12. McCurry. Japan deaths spark concerns over arthritis drug. Lancet. 2004;363:461. Doi: 10.1016/ S0140-6736(04)15527-X.
  13. Sakai F, Noma S, Kurilwa Y, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol. 2005;15:173-doi: 10.1007/s10165-005-0387-9.
  14. Бестаев Д.В., Божьева Л.А. Особенности интерстициального поражения легких по данным компьютерной томографии высокого разрешения у больных ревматоидным артритом в зависимости от воспалительной активности и длительности заболевания. Фарматека. 2014;20(293):75-8.
  15. Suissa S., et al. Antirheumatic drug use and the risk of acute myocardial infarction. Arthr Rheum. 2006;55(4):531-36. doi: 10.1002/art.22094.
  16. Suissa S., Hudson M., Ernst P Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthr Rheum. 2006;54(5):1435-39. doi: 10.1016/S8756-3452(08)70380-3.
  17. Ju J.H., Kim S.I., Lee J.H., et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthr Rheum. 2007;56:2094-96. Doi: 10.1002/ art.22666.
  18. Sato T., et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatol. (Oxford). 2009;48(10:1265. Doi: 10.1093/ rheumatology/kep227.
  19. Sawada T., et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatol. (Oxford). 2009;48(9):1069-72. doi: 10.1093/rheumatology/kep052
  20. Banks J., Banks C., Cheong B., et al. An epidemiological and clinical investigation of pulmonary function and respiratory symptoms in patients with rheumatoid arthritis. Quart J Med. 1992;85(307-308):795-806. Doi: 10.1093/ oxfordjournals.qjmed.a068716.
  21. Bartels C.M., Bell C.L., Shinki K., et al. Changing trends in serious extra-articular manifestations of rheumatoid arthritis among United State veterans over 20 years. Rheumatol. (Oxford). 2010;49(9):1670-75. Doi: 10.1093/ rheumatology/keq135.
  22. Bas S., et al. Association of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis. Rheumatol. (Oxford). 2000;39(10):1082-88. Doi: 10.1093/ rheumatology/39.10.1082
  23. Jurik A.G., Davidsen D., Graudal H. Prevalence of pulmonary involvement in rheumatoid arthritis and its relationship to some characteristics of the patients. A radiological and clinical study. Scand J Rheumatol. 1982;11(4):217-24. doi: 10.3109/03009748209098194.
  24. Feidman M., Brennan F, Maini R.N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996;14:397-440. Doi: 10.1146/ annurev.immunol.14.1.397
  25. Elias J.A. Tumor necrosis factor interacts with interleukin-1 and interferons to inhibit fibroblast proliferation via fibroblast prostaglandin-dependent and -independent mechanisms. Am Rev Respir Dis. 1988;138:652-58. Doi: 10.1007/ BF01300378.
  26. Chikura B., Lane S., Dawson J.K. Clinical expression of leflunomide-induced pneumonitis. Rheumatol. (Oxford). 2009;48(9):1065-68. Doi: 10.1093/ rheumatology/kep050.
  27. Noh S., Yadav R., Li M., et al. Use of leflunomide in patients with chronic hypersensitivity pneumonitis. BMC. Pulm Med. 2020;20(1):199. [Epub 2020 Jul 21]. doi: 10.1186/s12890-020-01227-2

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies